Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis

Hypomagnesemia is a serious adverse event for patients treated with cetuximab, an inhibitor of endothelial growth factor receptor (EGFR). However, no significant association has yet been established between cetuximab and hypomagnesemia in randomized controlled clinical trials (RCTs). The present stu...

Descripción completa

Detalles Bibliográficos
Autores principales: CHEN, PENG, WANG, LONG, LI, HAO, LIU, BING, ZOU, ZUI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700916/
https://www.ncbi.nlm.nih.gov/pubmed/23833666
http://dx.doi.org/10.3892/ol.2013.1301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700916/
https://www.ncbi.nlm.nih.gov/pubmed/23833666
http://dx.doi.org/10.3892/ol.2013.1301

Ejemplares similares